common.study.topics.clinical

Testing Experimental Treatment for Cystic Fibrosis

common.study.values.description

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - ABBV-3067

Tablet or capsule taken orally

Drug - Placebo ABBV-3067

Tablet or capsule taken orally

Drug - ABBV-2222

Capsule taken orally

Drug - Placebo ABBV-2222

Capsule taken orally

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation

common.study.values.clinical-trial-id

NCT03969888

participant.views.study.view.id

eVOjza